Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Gavila, Joaquín; Oliveira, Mafalda; Pascual, Tomas; Pérez-García, José; González, Xavier; Canes, Jordi; Pare, Laia; Calvo, Isabel; Ciruelos, Eva; Muñoz, Montserrat; Virizuela, Juan-A; Ruiz, Isabel; Andrés, Raquel; Perello, Antonia; Martínez-García, Jerónimo; Morales, Serafin; Marín-Aguilera, Mercedes; Martínez, Debora; Quero, Juan-C; Llombart-Cussac, Antonio; Prat, Aleix

RICSMUR Principal
→
02. Servicio Murciano de Salud (SMS)
→
02.01. Área de Salud I Murcia Oeste
→
02.01.01. Investigación y comunicación científica
→
Ver ítem

dc.contributor.author	Gavila, Joaquín
dc.contributor.author	Oliveira, Mafalda
dc.contributor.author	Pascual, Tomas
dc.contributor.author	Pérez-García, José
dc.contributor.author	González, Xavier
dc.contributor.author	Canes, Jordi
dc.contributor.author	Pare, Laia
dc.contributor.author	Calvo, Isabel
dc.contributor.author	Ciruelos, Eva
dc.contributor.author	Muñoz, Montserrat
dc.contributor.author	Virizuela, Juan-A
dc.contributor.author	Ruiz, Isabel
dc.contributor.author	Andrés, Raquel
dc.contributor.author	Perello, Antonia
dc.contributor.author	Martínez-García, Jerónimo
dc.contributor.author	Morales, Serafin
dc.contributor.author	Marín-Aguilera, Mercedes
dc.contributor.author	Martínez, Debora
dc.contributor.author	Quero, Juan-C
dc.contributor.author	Llombart-Cussac, Antonio
dc.contributor.author	Prat, Aleix
dc.date.accessioned	2026-01-19T16:03:14Z
dc.date.available	2026-01-19T16:03:14Z
dc.date.issued	2019-01-09
dc.identifier.citation	Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, et al. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Med. diciembre de 2019;17(1):8.
dc.identifier.issn	1741-7015
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/23674
dc.language.iso	eng
dc.publisher	BMC
dc.rights	Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/deed.es	*
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subject.mesh	Breast Neoplasms/drug therapy
dc.subject.mesh	Cardiotoxicity/epidemiology
dc.subject.mesh	Chemotherapy, Adjuvant/adverse effects/methods
dc.subject.mesh	Doxorubicin/administration & dosage/adverse effects/analogs & derivatives
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoadjuvant Therapy/adverse effects/methods
dc.subject.mesh	Paclitaxel/administration & dosage/adverse effects
dc.subject.mesh	Polyethylene Glycols/administration & dosage/adverse effects
dc.subject.mesh	Receptor, ErbB-2
dc.subject.mesh	Trastuzumab/administration & dosage/adverse effects
dc.title	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	30621698
dc.relation.publisherversion	https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1233-1
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.identifier.doi	10.1186/s12916-018-1233-1
dc.journal.title	BMC Medicine